Isabelle Riviere

Director/Board Member at Centre For Commercialization of Cancer Immunotherapy

Health Technology

Profile

Isabelle Riviere is the founder of Juno Therapeutics, Inc. which was founded in 2013.
Currently, she holds the position of Director at the Centre For Commercialization of Cancer Immunotherapy.

Isabelle Riviere active positions

Companies	Position	Start
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada.	Director/Board Member	-

All active positions of Isabelle Riviere

Former positions of Isabelle Riviere

Companies	Position	End
JUNO THERAPEUTICS INC	Founder	-

See the detail of Isabelle Riviere's experience

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Isabelle Riviere's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Private companies	2
Juno Therapeutics, Inc. Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA.	Health Technology
Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy Centre For Commercialization of Cancer Immunotherapy provides solution for the development, translation, and commercialization of cancer immunotherapy and regenerative medicine. It offers clinical research unit, contract research organization, and innovation and commercialization unit services. The company was founded by Lambert Busque, Denis-Claude Roy and is headquartered in Montréal, Canada.